Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
Phase 2
Completed
NCT00183820
| Condition | Testicular Cancer, Germ Cell Neoplasm |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | University of Southern California |
|---|
| Status | Completed |
|---|
| Enrollment | 30 participants |
|---|
| Interventions | paclitaxel, gemcitabine, and oxaliplatin |
|---|
| Start date | Nov, 2004 |
|---|
| Completion date | Dec, 2015 |
|---|
| Results posted | Jul 1, 2026 |
|---|
Summary
This is a study for patients with advanced testicular cancer. This research study involves treatment with oxaliplatin, paclitaxel, and gemcitabine, which is an investigational chemotherapy combination. This study is for patients who have not responded to standard cisplatin-containing chemotherapy or the cancer has returned after such treatment. This research is being done to assess the effectiveness of the proposed combination of medications for this type of cancer.
Tumor Response
From start of study drug until the date of first documented progression or date of death from any cause, whichever came first, assessed every 6 weeks, through study completion, up to 9 years · Participants
| Paclitaxel, Gemcitabine, and Oxaliplatin | 2 Participants |
|---|
| Paclitaxel, Gemcitabine, and Oxaliplatin | 7 Participants |
|---|
| Paclitaxel, Gemcitabine, and Oxaliplatin | 15 Participants |
|---|
| Paclitaxel, Gemcitabine, and Oxaliplatin | 5 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.